Quick Answer
Tectonic Therapeutic, Inc. reported Net Income of -$74.15 million for fiscal year 2025.
Tectonic Therapeutic, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$74.15M -27.9% |
-$57.98M -35.4% |
-$42.82M +59.6% |
-$105.89M +11.1% |
-$119.13M +0.5% |
-$119.71M -64.1% |
| Diluted EPS | -$4.05 +40.7% |
-$6.83 +79.8% |
-$33.76 -1295.0% |
-$2.42 +12.9% |
-$2.78 | — |
| Total Assets | $261.04M +70.7% |
$152.91M +288.1% |
$39.40M -62.1% |
$103.95M -49.0% |
$203.84M -24.8% |
$271.23M +35.3% |
| Cash and Equivalents | $253.80M +79.7% |
$141.24M +390.9% |
$28.77M -68.9% |
$92.56M -51.2% |
$189.57M -27.0% |
$259.68M +38.8% |
| Stockholders Equity | $251.33M +78.5% |
$140.78M +266.3% |
-$84.64M -85.4% |
-$45.65M -126.9% |
$169.48M -33.4% |
$254.34M +36.7% |
| R&D Expense | $63.49M +53.5% |
$41.36M +11.9% |
$36.97M -48.8% |
$72.19M -13.1% |
$83.11M -4.7% |
$87.24M +58.7% |
| Operating Income | -$84.04M -44.9% |
-$58.02M -29.9% |
-$44.65M +57.7% |
-$105.43M +11.3% |
-$118.84M +1.2% |
-$120.23M -58.6% |
| Shares Outstanding | 18.74M +26.1% |
14.86M +955.3% |
1.41M -96.8% |
43.92M +0.6% |
43.65M +0.0% |
43.65M +38.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$19.04M | -7.4% | +4.7% |
| Diluted EPS | September 30, 2025 | -$1.02 | +15.0% | +4.7% |
| Total Assets | September 30, 2025 | $277.00M | +64.2% | -6.2% |
| Cash and Equivalents | September 30, 2025 | $268.44M | +68.7% | -6.6% |
| Stockholders Equity | September 30, 2025 | $267.53M | +77.9% | -5.7% |
| R&D Expense | September 30, 2025 | $16.93M | +18.2% | -1.5% |
| Operating Income | September 30, 2025 | -$21.89M | -11.5% | +2.0% |
| Shares Outstanding | September 30, 2025 | 18.71M | +26.9% | +0.0% |
- Tectonic Therapeutic, Inc. reported Net Income of -$74.15 million for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed a decrease of -27.9% in Net Income compared to the prior fiscal year.
- Tectonic Therapeutic, Inc. reported Diluted EPS of $4.05 per share (loss) for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed an increase of +40.7% in Diluted EPS compared to the prior fiscal year.
- Tectonic Therapeutic, Inc. reported Total Assets of $261.04 million for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed an increase of +70.7% in Total Assets compared to the prior fiscal year.
- Tectonic Therapeutic, Inc. reported Cash and Equivalents of $253.80 million for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed an increase of +79.7% in Cash and Equivalents compared to the prior fiscal year.
- Tectonic Therapeutic, Inc. reported Stockholders Equity of $251.33 million for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed an increase of +78.5% in Stockholders Equity compared to the prior fiscal year.
- Tectonic Therapeutic, Inc. reported R&D Expense of $63.49 million for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed an increase of +53.5% in R&D Expense compared to the prior fiscal year.
- Tectonic Therapeutic, Inc. reported Operating Income of -$84.04 million for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed a decrease of -44.9% in Operating Income compared to the prior fiscal year.
- Tectonic Therapeutic, Inc. reported Shares Outstanding of 18.74 million shares for fiscal year 2025.
- Tectonic Therapeutic, Inc. showed an increase of +26.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: